The early aim and later failure
Ipamorelin raised growth hormone, yet left the patient benefit unproved
The makers hoped to increase growth hormone while leaving stress hormones alone. That worked in animals; patient testing later ended without a proved treatment gain.
The makers wanted one hormone to rise, not several
Novo Nordisk made Ipamorelin hoping to keep stress hormones unchanged during growth-hormone release. Animal results matched that aim; later patients had no clear treatment benefit.
A peptide has small chemicals called amino acids joined in a string. Ipamorelin has five linked amino acids, put together in a lab.
Your body uses amino acids to make proteins for growth and repair. Proteins are substances your body makes for these and many other jobs.
A gland below your brain stores growth hormone, which helps growth and repair. After Ipamorelin, the gland lets growth hormone out of storage.
Ghrelin is a natural hormone that helps control hunger; Ipamorelin copies ghrelin's action. Older test drugs caused unwanted hormone rises as well; Ipamorelin largely avoided those rises.
In healthy volunteers, growth hormone briefly increased, peaking around forty minutes. About two hours passed before the falling drug level dropped by half.
Some people tried Ipamorelin outside studies and described easier sleep or less soreness. A trial hasn't checked whether Ipamorelin caused those reported gains.
Patients after bowel surgery had no proved gain in keeping food down. Read about the effects for reported changes and possible harms.
Ipamorelin lacks approval from any drug authority for treating illness. Your blood test can change without your health getting better.
Healthy men had a brief rise that soon faded
These tests followed healthy men briefly, with no months of treatment. The study tried five amounts, given to the men through veins.
Men receiving more Ipamorelin had more of the drug in their blood. Falling levels then took about 2 hours to halve [2].
About 40 minutes after treatment, growth hormone reached its peak [2]. The hormone level fell afterward, rather than staying high.
Growth hormone normally comes out in brief bursts in your body. These tests measured a burst, without testing sleep or healing.
A separate comparison used male rats, rather than men. An older drug for growth-hormone release disappeared from rat blood far faster than Ipamorelin.
Much of the Ipamorelin left those rats through urine and bile. Bile is fluid the liver makes to help digest food.
After treatment through the nose, about 20% reached rat blood [10]. The share entering your blood remains untested, despite the rat finding.
The studies tell you about short blood changes, leaving lasting gains untested. You can check the timing findings before taking a brief hormone burst as evidence that you will sleep more soundly, heal sooner, or stay healthier over the years.
Unchanged stress hormones left other safety questions open
The early work involved animals and gland cells in dishes. Nobody tested people receiving Ipamorelin for years to check lasting safety.
The amount of growth hormone released matched an older drug's result. Even much larger amounts left cortisol, the body's stress hormone, unchanged [1].
The other stress-hormone blood result stayed unchanged too. Prolactin helps with milk production; that hormone's level mostly stayed unchanged as well [1].
Growth hormone stays stored inside gland cells until release begins. After Ipamorelin, calcium increased inside the cells and helped release the stored hormone.
Calcium helps bones, but also helps cells respond to a drug. The cell test explains release, leaving your health benefit unproved.
The body has more than one way to start growth-hormone release. CJC-1295 acts through a different way, which prompted interest in pairing the drugs.
No human comparison establishes a health gain from the pair. You can examine the pairing research for what animal tests leave unanswered.
The rat growth result did not settle the patient question
This bone study tested adult female rats, without testing people with painful joints. For 15 days, each rat had three daily shots under the skin.
One group received 18 micrograms daily and grew 44 micrometers of bone each day. Another received 90 micrograms and grew 50 micrometers daily.
The group receiving 450 micrograms grew 52 micrometers daily. Without Ipamorelin, daily growth was 42 micrometers [4].
Micrograms measure tiny drug amounts: millionths of a gram. Micrometers measure tiny lengths: thousandths of a millimeter.
The higher-amount rat groups had more bone growth. Blood tests for growth-related proteins and bone activity stayed unchanged.
In 2024, ferrets had treatment during chemotherapy, treatment with cancer drugs. Later weight loss was about 24% smaller, although vomiting continued [5].
The Phase 2 trial tested 114 people after bowel surgery. Phase means a testing stage; these patients reached the middle stage.
Patients ate sooner with Ipamorelin than with placebo, treatment containing no Ipamorelin. But the difference was too uncertain to prove a benefit [3].
You still lack a proved treatment gain from that patient test. Read the reported changes with the failed comparison in mind.
Ipamorelin’s withdrawn pharmacy request did not grant approval
No country has approved Ipamorelin as a treatment. Novo Nordisk developed the drug in the 1990s, before researchers tested bowel recovery.
That Phase 2 patient trial failed to prove its hoped-for benefit [3]. Development ended without proving patients could keep food down sooner.
Ipamorelin is banned in sport at all times by the World Anti-Doping Agency. Urine tests can detect the drug and pieces left after breakdown [11].
FDA's page current as of April 22, 2026 lists a withdrawn request. The request asked FDA to list the drug as an ingredient pharmacies could use when preparing medicine for individual patients.
The request named Ipamorelin acetate, Ipamorelin joined to another chemical during preparation. Acetate describes that form of the drug, not table salt added to a vial.
The people seeking that listing later withdrew their request, without gaining approval. FDA hasn't clarified whether an ordinary pharmacy can prepare Ipamorelin for you.
Facilities making larger batches face a separate safety list. Ipamorelin acetate remains in Category 2 there, meaning FDA has safety concerns.
A pharmacy advice committee held its review on October 29, 2024. The review gave no approval, and the withdrawn request gave none either.
The references page links to the studies and official pages. You are reading a research guide; no treatment or products are supplied here.